PHGE - BiomX Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
8.00
-0.00 (-0.00%)
At close: 3:57PM EST
Stock chart is not supported by your current browser
Previous Close8.00
Open0.00
Bid7.85 x 800
Ask12.99 x 900
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume10,480
Market Cap182.22M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    BiomX Announces Completion of Enrollment for Double-Blind, Placebo-Controlled Clinical Study of BX001 in Acne-Prone Skin

    BX001 is a topically administered gel comprised of a cocktail of naturally occurring phage targeting Cutibacterium acnes (C. acnes, formerly taxonomically classified as Propionibacterium acnes, or P. acnes), a bacterium implicated in the pathophysiology of acne vulgaris. The primary endpoints of the randomized, double-blind, dose-ranging, vehicle-controlled study are safety and tolerability.

  • Business Wire

    BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis

    - Data presented at the presidential plenary translational session of the AASLD conference

  • PR Newswire

    Stone Street Group Initiates Coverage On BiomX Inc.

    NEW YORK , Nov. 12, 2019 /PRNewswire/ -- Stone Street Group has announced it has initiated coverage on BiomX Inc (NYSE: PHGE). The full report can be found here: PHGE Report Key Report Highlights: Chardan ...

  • Business Wire

    BiomX Appoints Russell G. Greig, Ph.D, as Chairman of the Board of Directors and Lynne Sullivan as Board Director

    BiomX Inc. (NYSE: PHGE), a microbiome company developing both natural and engineered phage therapies, today announced the election of Russell G. Greig, Ph.D., as Chairman of the Board of Directors and Lynne Sullivan as Board Director. Dr. Greig brings extensive leadership experience in the pharmaceutical and biotech sectors in research and development and business roles, including three decades at GlaxoSmithKline, most recently as President of SR One, GlaxoSmithKline’s corporate venture group. Ms. Sullivan brings extensive expertise in finance having served in senior roles in several leading pharmaceutical and biotech companies including as Senior Vice President of Finance for Biogen, where she worked for over a decade.

  • Business Wire

    BiomX To Present at Plenary Session of the AASLD Liver Conference

    BiomX Inc. , a microbiome company developing both natural and engineered phage therapies, today announced that BiomX’s Chief Medical Officer, Sailaja Puttagunta, M.D., will present pre-clinical data from the company’s liver program at the plenary session of the American Association for The Study of Liver Diseases taking place in Boston, Massachusetts from November 8 - November 12, 2019.